This article is more than 5 years old. Information may no longer be current.

FDA approves new rapid HIV-1 test

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a new single-use, rapid test for the detection of antibodies to HIV-1 in human venipuncture whole blood, finger-prick blood or plasma specimens, according to an FDA press release.

The INSTI HIV-1 antibody test — manufactured by bioLytical Laboratories Inc., in Richmond British Columbia, Canada — delivers results in as little as 1 minute, in contrast to the 10 to 20 minutes it takes for the six previously approved rapid HIV tests to deliver results.

The new test may be used in clinical laboratories, in public health laboratories and in point-of-care settings and is classified as moderate complexity under Clinical Laboratory Improvements Amendments.

According to the press release, the overall sensitivity of the test is 99.8% (95% CI, 99.3%-99.9%) in finger-prick whole blood; 99.9% (95% CI, 99.5%-100%) in venipuncture whole blood; and 99.9% (95% CI, 99.5%-100%) in plasma.

Overall specificity for the different types is 99.5% (95% CI, 99.0%-99.8%) in finger-prick whole blood; 100% (95% CI, 99.7-100) in venipuncture whole blood; and 100% (95% CI, 99.7-100) in plasma for the detection of antibodies to HIV-1.

The test is not recommended to be used for screening of blood donors.

Follow InfectiousDiseaseNews.com on Twitter.